Illumina, Inc. v. BGI Genomics Co., Ltd
Opinion
trial_court Opinion
1 2 3 4 UNITED STATES DISTRICT COURT 5 NORTHERN DISTRICT OF CALIFORNIA 6 7 ILLUMINA, INC., et al., Case No. 19-cv-03770-WHO
8 Plaintiffs,
ORDER RE MOTIONS FOR
9 v. PRELIMINARY INJUCTIONS
10 BGI GENOMICS CO., LTD, et al., Defendants. 11
12 Before me are two motions for a preliminary injunction filed by plaintiffs Illumina Inc. and 13 Illumina Cambridge Ltd. (collectively, “Illumina”) in two related cases before me.1 Illumina 14 contends that defendants BGI Genomics Co., Ltd., BGI Americas Corp., MGI Tech Co., Ltd., 15 MGI Americas, Inc., and Complete Genomics, Inc. (collectively, “BGI”) infringe five of its 16 patents related to DNA sequencing in two sets of its products. I find that Illumina has established 17 a likelihood of infringement in both cases. Moreover, BGI has failed to identify significant 18 questions as to the validity of Illumina’s patents, several of which have been challenged and found 19 to be valid in the past. I further find that Illumina would suffer irreparable harm as a result of 20 BGI’s infringing activities. For these…